Balázs Hankó
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Balázs Hankó has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Zoltán Vincze
Semmelweis University
3 shared publicationsPéter Kumli
Semmelweis University
2 shared publicationsAntal Samu
Semmelweis University
1 shared publicationMargit Kázmér
Semmelweis University
1 shared publication- Romána Zelkó
University Pharmacy Department of Pharmacy Administration, Semmelweis University, 7-9 Hőgyes Street, 1092 Budapest, Hungary
1 shared publication Zsuzsanna Hrágyel
Semmelweis University
1 shared publication
Latest Publications
- 23 December 2006
- Published by Springer Nature in Pharmacy World & Science
- Vol. 29 (2) , 58-66
Self-reported medication and lifestyle adherence in Hungarian patients with Type 2 diabetes
Background: Type 2 diabetes is a complex disorder that requires the patient to pay constant attention to diet, physical activity, glucose monitoring and medication. Objective: To evaluate the medication, lifestyle adherence and factors associated to these in Type 2 diabetes in Hungarian patients. Setting: Fourteen community pharmacies in Hungary between March and May 2004. Method: A questionnaire was given to every tenth Type 2 diabetic patient who presented to one of the 14 pharmacies included in this study with a prescription for oral antidiabetics, oral antidiabetics and insulin or exclusively insulin. For the latter two groups, the prerequisite for inclusion in the study was also that their diabetes had developed after the age of 35 and that at some in their treatment regimen they had taken only oral antidiabetics. These latter two criteria were controlled in the patient's general practitioners' (GP) database. General and diabetes-related data were collected in the questionnaire, and the adherence and lifestyle of the participant were assessed. An adapted and validated Hungarian version of the EQ-5D (EuroQol Group, 1993) quality-of-life questionnaire was also included. Descriptive and χ2 test statistical methods and two sample t-test were used. A significance level of PMain outcome measure: Patient self-reported adherence to diet, physical activity, self monitoring of blood glucose, purchasing of drug(s), drug regimen, association of demographic factors, treatment, lifestyle and quality of life on adherence. Results: Of the 220 questionnaires distributed to diabetic patients, 151 were returned, of which 142 were evaluated (nine did not satisfy the above-mentioned inclusion criteria). With respect to the factors assessed, sub-optimal adherence was assessed for: diet (76.8%), physical activity (33.8%), self-monitoring of blood glucose (81%), drug purchasing (20.4%) and drug taking (52.1%). Smokers comprised 14.8% of the respondents, while 8.5% were heavy drinkers. Fewer than five meals a day were eaten by 46.5% of the patients, and about 43.6% of the patients did not self-monitor blood glucose. The results indicate few significant associations between at least one of the four main areas of adherence (diet, physical activity, purchasing of drug(s), drug regimen) and body mass index, GP consultation frequency, quality-of-life parameters and EQ-5D index. Conclusion: The adherence of Hungarian Type 2 diabetics in some areas does not reach optimal levels, especially for diet, self-monitoring, drug purchasing and adherence to drug taking.
- 23 December 2006
- Published by Springer Nature in Pharmacy World & Science
- Vol. 29 (2) , 58-66
Self-reported medication and lifestyle adherence in Hungarian patients with Type 2 diabetes
Background: Type 2 diabetes is a complex disorder that requires the patient to pay constant attention to diet, physical activity, glucose monitoring and medication. Objective: To evaluate the medication, lifestyle adherence and factors associated to these in Type 2 diabetes in Hungarian patients. Setting: Fourteen community pharmacies in Hungary between March and May 2004. Method: A questionnaire was given to every tenth Type 2 diabetic patient who presented to one of the 14 pharmacies included in this study with a prescription for oral antidiabetics, oral antidiabetics and insulin or exclusively insulin. For the latter two groups, the prerequisite for inclusion in the study was also that their diabetes had developed after the age of 35 and that at some in their treatment regimen they had taken only oral antidiabetics. These latter two criteria were controlled in the patient's general practitioners' (GP) database. General and diabetes-related data were collected in the questionnaire, and the adherence and lifestyle of the participant were assessed. An adapted and validated Hungarian version of the EQ-5D (EuroQol Group, 1993) quality-of-life questionnaire was also included. Descriptive and χ2 test statistical methods and two sample t-test were used. A significance level of PMain outcome measure: Patient self-reported adherence to diet, physical activity, self monitoring of blood glucose, purchasing of drug(s), drug regimen, association of demographic factors, treatment, lifestyle and quality of life on adherence. Results: Of the 220 questionnaires distributed to diabetic patients, 151 were returned, of which 142 were evaluated (nine did not satisfy the above-mentioned inclusion criteria). With respect to the factors assessed, sub-optimal adherence was assessed for: diet (76.8%), physical activity (33.8%), self-monitoring of blood glucose (81%), drug purchasing (20.4%) and drug taking (52.1%). Smokers comprised 14.8% of the respondents, while 8.5% were heavy drinkers. Fewer than five meals a day were eaten by 46.5% of the patients, and about 43.6% of the patients did not self-monitor blood glucose. The results indicate few significant associations between at least one of the four main areas of adherence (diet, physical activity, purchasing of drug(s), drug regimen) and body mass index, GP consultation frequency, quality-of-life parameters and EQ-5D index. Conclusion: The adherence of Hungarian Type 2 diabetics in some areas does not reach optimal levels, especially for diet, self-monitoring, drug purchasing and adherence to drug taking.
- 1 June 2005
- Published by Springer Nature in Pharmacy World & Science
- Vol. 27 (3) , 263-265
Antidiabetic Drug Utilization in Hungary
Objective: To evaluate the utilization trends of antidiabetics in Hungary. Method: The analysis includes the drugs of antidiabetic therapy which were registered between 1998 and 2002 in Hungary. The consumption of antidiabetic drugs was analyzed by the ATC/Defined Daily Dose (DDD) method. The data used in this study were derived from the National Health Insurance and from MIS Consulting Company. Results: Between 1998 and 2002, the total consumption of antidiabetics increased by 41.8%, and reached 47.59 DDD/1000 inhabitants/day in 2002. The consumption of oral antidiabetics (OAD) increased by 33.41% (33.86 DDD/1000 inhabitants/d ay in 2002), while in the case of insulin the increase was 67.8% (13.74 DDD/1000 inhabitants/day). Sulphonylureas were the most frequently used class (21.11 DDD/1000 inhabitants/day in 2002). Glibenclamide was the most frequently used antidiabetic drug (12.63 DDD/1000 inhabitants/day in 2002). Conclusion: The insulin class had greater emphasis in therapy. Among OAD, the consumption rate of sulphonylureas decreased and the consumption rate of Biguanides and acarbose increased. By 2002 metformin replaced 90% of the buformin in use. The limited effect of therapeutic recommendations could explain these changes, although the out-of-date buformin and the non-micronized glibenclamide were still in use in 2002.
- 1 June 2005
- Published by Springer Nature in Pharmacy World & Science
- Vol. 27 (3) , 263-265
Antidiabetic Drug Utilization in Hungary
Objective: To evaluate the utilization trends of antidiabetics in Hungary. Method: The analysis includes the drugs of antidiabetic therapy which were registered between 1998 and 2002 in Hungary. The consumption of antidiabetic drugs was analyzed by the ATC/Defined Daily Dose (DDD) method. The data used in this study were derived from the National Health Insurance and from MIS Consulting Company. Results: Between 1998 and 2002, the total consumption of antidiabetics increased by 41.8%, and reached 47.59 DDD/1000 inhabitants/day in 2002. The consumption of oral antidiabetics (OAD) increased by 33.41% (33.86 DDD/1000 inhabitants/d ay in 2002), while in the case of insulin the increase was 67.8% (13.74 DDD/1000 inhabitants/day). Sulphonylureas were the most frequently used class (21.11 DDD/1000 inhabitants/day in 2002). Glibenclamide was the most frequently used antidiabetic drug (12.63 DDD/1000 inhabitants/day in 2002). Conclusion: The insulin class had greater emphasis in therapy. Among OAD, the consumption rate of sulphonylureas decreased and the consumption rate of Biguanides and acarbose increased. By 2002 metformin replaced 90% of the buformin in use. The limited effect of therapeutic recommendations could explain these changes, although the out-of-date buformin and the non-micronized glibenclamide were still in use in 2002.
- Open Access
- 15 July 2004
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 61 (14) , 1437-1438
Patient interest in receiving diabetes care in Hungarian community pharmacies
Balázs Hanko, Pharm.D., Ph.D., Zoltán Vincze, M.Sc., Ph.D.; Patient interest in receiving diabetes care in Hungarian community pharmacies, American Journal of
- 15 July 2004
- Published by Oxford University Press (OUP) in American Journal of Health-System Pharmacy
- Vol. 61 (14) , 1437-1438
Open AccessPatient interest in receiving diabetes care in Hungarian community pharmacies
Balázs Hanko, Pharm.D., Ph.D., Zoltán Vincze, M.Sc., Ph.D.; Patient interest in receiving diabetes care in Hungarian community pharmacies, American Journal of